| First Author | Zhou Z | Year | 2020 |
| Journal | Am J Pathol | Volume | 190 |
| Issue | 3 | Pages | 614-629 |
| PubMed ID | 31972159 | Mgi Jnum | J:291608 |
| Mgi Id | MGI:6435345 | Doi | 10.1016/j.ajpath.2019.11.012 |
| Citation | Zhou Z, et al. (2020) Toll-Like Receptor 5 Signaling Ameliorates Liver Fibrosis by Inducing Interferon beta-Modulated IL-1 Receptor Antagonist in Mice. Am J Pathol 190(3):614-629 |
| abstractText | Bacterial flagellin, recognized by cell surface of Toll-like receptor (TLR) 5, is a potent activator of many types of cells, leading to the activation of innate or adaptive immunity, which are pivotal in regulating fibrotic process. However, the exact role of TLR5 signaling in hepatic fibrogenesis remains unclear, and this study aims to elucidate its underlying mechanisms. Flagellin was injected to hepatotoxin- and cholestasis-induced liver fibrosis murine models. Flagellin-induced TLR5 activation significantly decreased the severity of liver fibrosis. Interestingly, the expression levels of IL-1 receptor antagonist (IL1RN) and interferon (IFN)beta markedly increased in fibrotic livers on flagellin treatment. Consistently, in vivo activation of TLR5 signaling markedly increased IFNbeta and IL1RN expression in the livers. Notably, flagellin injection significantly exacerbated the severity of liver fibrosis in IFN-alpha/beta receptor 1 (IFNAR1) knockout mice. Furthermore, hepatic expression of IL1RN in the fibrotic livers of IFNAR1 knockout mice was significantly lower than those of wild-type mice. In support of these findings, flagellin-mediated IL1RN production is not sufficient to alleviate the severity of hepatic fibroinflammatory responses in IFNAR1-deficient milieu. Finally, hepatic stellate cells treated with IL1RN had significantly decreased cellular activation and its associated fibrogenic responses. Collectively, manipulation of TLR5 signaling may be a promising therapeutic strategy for the treatment of liver fibrosis. |
